"Poly(ADP-ribose) Polymerase Inhibitors/pharmacology"[MAJR] - Search Results

Year	Number of Results
2014	6
2015	83
2016	90
2017	119
2018	128
2019	157
2020	174
2021	199
2022	152
2023	121
2024	80

1

Targeting DNA damage response pathways in cancer.

Groelly FJ, Fawkes M, Dagg RA, Blackford AN, Tarsounas M. Groelly FJ, et al. Nat Rev Cancer. 2023 Feb;23(2):78-94. doi: 10.1038/s41568-022-00535-5. Epub 2022 Dec 5. Nat Rev Cancer. 2023. PMID: 36471053 Review.

2

PARP inhibitor resistance: the underlying mechanisms and clinical implications.

Li H, Liu ZY, Wu N, Chen YC, Cheng Q, Wang J. Li H, et al. Mol Cancer. 2020 Jun 20;19(1):107. doi: 10.1186/s12943-020-01227-0. Mol Cancer. 2020. PMID: 32563252 Free PMC article. Review.

3

Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology.

Bruin MAC, Sonke GS, Beijnen JH, Huitema ADR. Bruin MAC, et al. Clin Pharmacokinet. 2022 Dec;61(12):1649-1675. doi: 10.1007/s40262-022-01167-6. Epub 2022 Oct 11. Clin Pharmacokinet. 2022. PMID: 36219340 Free PMC article. Review.

4

BRCAness, Homologous Recombination Deficiencies, and Synthetic Lethality.

Murai J, Pommier Y. Murai J, et al. Cancer Res. 2023 Apr 14;83(8):1173-1174. doi: 10.1158/0008-5472.CAN-23-0628. Cancer Res. 2023. PMID: 37057596

5

Mechanisms of PARP inhibitor sensitivity and resistance.

D'Andrea AD. D'Andrea AD. DNA Repair (Amst). 2018 Nov;71:172-176. doi: 10.1016/j.dnarep.2018.08.021. Epub 2018 Aug 23. DNA Repair (Amst). 2018. PMID: 30177437 Review.

6

Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency.

Cong K, Peng M, Kousholt AN, Lee WTC, Lee S, Nayak S, Krais J, VanderVere-Carozza PS, Pawelczak KS, Calvo J, Panzarino NJ, Turchi JJ, Johnson N, Jonkers J, Rothenberg E, Cantor SB. Cong K, et al. Mol Cell. 2021 Aug 5;81(15):3128-3144.e7. doi: 10.1016/j.molcel.2021.06.011. Epub 2021 Jul 2. Mol Cell. 2021. PMID: 34216544 Free PMC article.

7

Molecular Genetics of Prostate Cancer and Role of Genomic Testing.

Akhoundova D, Feng FY, Pritchard CC, Rubin MA. Akhoundova D, et al. Surg Pathol Clin. 2022 Dec;15(4):617-628. doi: 10.1016/j.path.2022.08.002. Epub 2022 Oct 13. Surg Pathol Clin. 2022. PMID: 36344179 Free article. Review.

8

Comparative Analyses of Poly(ADP-Ribose) Polymerase Inhibitors.

Guha M, Sobol Z, Martin M, Hemkens M, Sung T, Rubitski E, Spellman R, Finkelstein M, Khan N, Hu W. Guha M, et al. Int J Toxicol. 2022 Dec;41(6):442-454. doi: 10.1177/10915818221121325. Epub 2022 Aug 21. Int J Toxicol. 2022. PMID: 35989659

9

Poly(ADP-ribose) polymerase activity and inhibition in cancer.

Dulaney C, Marcrom S, Stanley J, Yang ES. Dulaney C, et al. Semin Cell Dev Biol. 2017 Mar;63:144-153. doi: 10.1016/j.semcdb.2017.01.007. Epub 2017 Jan 10. Semin Cell Dev Biol. 2017. PMID: 28087320 Review.

10

Development of Next-Generation Poly(ADP-Ribose) Polymerase 1-Selective Inhibitors.

Ngoi NYL, Leo E, O'Connor MJ, Yap TA. Ngoi NYL, et al. Cancer J. 2021 Nov-Dec 01;27(6):521-528. doi: 10.1097/PPO.0000000000000556. Cancer J. 2021. PMID: 34904816 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

1,144 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

1,144 results

Results by year